Trial Profile
A Phase 2b Study to Evaluate the Efficacy, Safety and PK of a Combination of Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fumarate for Treatment of HIV-1 Infection in Patients With DS-TB on a Rifampicin-based Regimen
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Bictegravir/emtricitabine/tenofovir alafenamide (Primary) ; Dolutegravir/lamivudine/tenofovir; Rifampicin
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms INSIGHT
- 02 Apr 2024 Planned End Date changed from 31 Dec 2024 to 31 Aug 2024.
- 02 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 13 Mar 2024 Status changed from active, no longer recruiting to recruiting.